Home >> Research Area >>Chromatin/Epigenetics>>Histone Methyltransferase>> 3-Deazaneplanocin A (DZNep) hydrochloride

3-Deazaneplanocin A (DZNep) hydrochloride

SAHH and ENZ2 inhibitor CAS# 120964-45-6

3-Deazaneplanocin A (DZNep) hydrochloride

Catalog No. BCC3604----Order now to get a substantial discount!

Product Name & Size Price Stock
3-Deazaneplanocin A (DZNep) hydrochloride: 5mg $449 In Stock
3-Deazaneplanocin A (DZNep) hydrochloride: 10mg Please Inquire In Stock
3-Deazaneplanocin A (DZNep) hydrochloride: 20mg Please Inquire Please Inquire
3-Deazaneplanocin A (DZNep) hydrochloride: 50mg Please Inquire Please Inquire
3-Deazaneplanocin A (DZNep) hydrochloride: 100mg Please Inquire Please Inquire
3-Deazaneplanocin A (DZNep) hydrochloride: 200mg Please Inquire Please Inquire
3-Deazaneplanocin A (DZNep) hydrochloride: 500mg Please Inquire Please Inquire
3-Deazaneplanocin A (DZNep) hydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of 3-Deazaneplanocin A (DZNep) hydrochloride

Number of papers citing our products

Chemical structure

3-Deazaneplanocin A (DZNep) hydrochloride

3D structure

Chemical Properties of 3-Deazaneplanocin A (DZNep) hydrochloride

Cas No. 120964-45-6 SDF Download SDF
PubChem ID 14563109 Appearance Powder
Formula C12H15ClN4O3 M.Wt 298.73
Type of Compound N/A Storage Desiccate at -20°C
Synonyms DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride
Solubility H2O : 50 mg/mL (167.38 mM; Need ultrasonic)
Chemical Name (1S,2R,5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol;hydrochloride
SMILES C1=CN=C(C2=C1N(C=N2)C3C=C(C(C3O)O)CO)N.Cl
Standard InChIKey UNSKMHKAFPRFTI-FDKLLANESA-N
Standard InChI InChI=1S/C12H14N4O3.ClH/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19;/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14);1H/t8-,10-,11+;/m1./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of 3-Deazaneplanocin A (DZNep) hydrochloride

Description3-Deazaneplanocin A hydrochloride is an inhibitor of histone methyltransferase.
Targetshistone methyltransferase    

Protocol

Cell experiment:[1]

Cell lines

Human acute myeloid leukemia (AML) cell

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

100-750 nM; 24-72h

Applications

DZNep induced apoptosis in cultured and primary AML cells. DZNep exhausted EZH2 levels, and inhibits trimethylation of lysine 27 on histone H3 in the AML HL-60 and OCI-AML3 cells. DZNep induced the levels of p16, p21, p27, and FBXO32 after cyclin E and HOXA9 levels run out.

Animal experiment:[2]

Animal models

 

Sprague-Dawley rats (120–140 g)

Dosage form

 

5μM DZNep for 24 h pre-treatment before experiment, orally taken with diets

Application

DZNep significantly reduced EZH2 expression and activity, and it increased lipid accumulation, inflammatory molecules and microRNAs in non-alcoholic fatty liver disease (NAFLD) mouse model.

Other notes

 

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Fiskus W1, Wang Y, Sreekumar A et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009 Sep 24;114(13):2733-43.

2. Vella S, Gnani D, Crudele A et al. EZH2 down-regulation exacerbates lipid accumulation and inflammation in vitro and in vivo NAFLD.Int J Mol Sci. 2013 Dec 12;14(12):24154-68.

3-Deazaneplanocin A (DZNep) hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

3-Deazaneplanocin A (DZNep) hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 3-Deazaneplanocin A (DZNep) hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.3475 mL 16.7375 mL 33.475 mL 66.9501 mL 83.6876 mL
5 mM 0.6695 mL 3.3475 mL 6.695 mL 13.39 mL 16.7375 mL
10 mM 0.3348 mL 1.6738 mL 3.3475 mL 6.695 mL 8.3688 mL
50 mM 0.067 mL 0.3348 mL 0.6695 mL 1.339 mL 1.6738 mL
100 mM 0.0335 mL 0.1674 mL 0.3348 mL 0.6695 mL 0.8369 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on 3-Deazaneplanocin A (DZNep) hydrochloride

3-Deazaneplanocin A (DZNep) hydrochloride is a selective inhibitor of ENZ2 inhibitor with IC50 value of 0.08-0.24 μM [1].
ENZ2 is a sub-unit of PRC2 and plays an important role in regulating cell proliferation and cell-cycle progression. It has been reported that ENZ2 is over-expressed in many tumors, including prostate, breast, bladder cancers and AML [2]. In HepG2 cell lines, DZNep treatment markedly induced the intracellular lipids increasement and TNF-αand TGF-βexpression in mRNA level by augmenting PA/OA-dependent lipid accumulation [3].
DZNep is a potent ENZ2 inhibitor. When tested with human acute myeloid leukemia (AML) HL-60 and OCI-AML3 cell lines, administration of DZNep induced cell apoptosis by depleting ENZ2, cyclin E and HOXA9 expressions and inducing p16, p21,p27 and FBXO32 expressions in a dose-dependent manner [2].
In high-fat/high-fructose diet fed (HFa/HFr-D) rat mouse model that resembles human NAFLD metabolically and histologically, DZNep functioned as the effective agent to anti-inflammatory and anti-fibrotic roles by inhibiting ENZ2 [3].
It is also reported that DZNep has the inhibitory activity for (SAHH (S-adenosylhomocysteine hydrolase) with Ki value of 50 pM [4].
References:
[1].    Kikuchi, J., et al., Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer, 2012. 78(2): p. 138-43.
[2].    Fiskus, W., et al., Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009. 114(13): p. 2733-43.
[3].    Vella, S., et al., EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD. Int J Mol Sci, 2013. 14(12): p. 24154-68.
[4].    Glazer, R.I., et al., 3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem Pharmacol, 1986. 35(24): p. 4523-7.

Featured Products
New Products
 

References on 3-Deazaneplanocin A (DZNep) hydrochloride

Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.[Pubmed:27365379]

Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):291-303.

BACKGROUND/AIM: Numerous studies have shown that breast cancer and epigenetic mechanisms have a very powerful interactive relation. The MCF7 cell line, representative of luminal subtype and the MDA-MB 231 cell line representative of mesenchymal-like subtype were treated respectively with a Histone Methyl Transferase Inhibitors (HMTi), 3-Deazaneplanocin hydrochloride (DZNep), two histone deacetylase inhibitors (HDACi), sodium butyrate (NaBu), and suberoylanilide hydroxamic acid (SAHA) for 48 h. MATERIALS AND METHODS: Chromatin immunoprecipitation (ChIP) was used to observe HDACis (SAHA and NaBu) and HMTi (DZNep) impact on histones and more specifically on H3K27me3, H3K9ac and H3K4ac marks with Q-PCR analysis of BRCA1, SRC3 and P300 genes. Furthermore, the HDACi and HMTi effects on mRNA and protein expression of BRCA1, SRC3 and P300 genes were checked. In addition, statistical analyses were used. RESULTS: In the MCF7 luminal subtype with positive ER, H3k4ac was significantly increased on BRCA1 with SAHA. On the contrary, in the MDA-MB 231 breast cancer cell line, representative of mesenchymal-like subtype with negative estrogen receptor, HDACis had no effect. Also, DZNEP decreased significantly H3K27me3 on BRCA1 in MDA-MB 231. Besides, on SRC3, a significant increase for H3K4ac was obtained in MCF7 treated with SAHA. And DZNEP had no effect in MCF7. Also, in MDA-MB 231 treated with DZNEP, H3K27me3 significantly decreased on SRC3 while H3K4ac was significantly increased in MDA-MB-231 treated with SAHA or NaBu for P300. CONCLUSION: Luminal and mesenchymal-like breast cancer subtype cell lines seemed to act differently to HDACis (SAHA and NaBu) or HMTi (DZNEP) treatments.

Description

3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor.

Keywords:

3-Deazaneplanocin A (DZNep) hydrochloride,120964-45-6,DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride,Natural Products,Histone Methyltransferase, buy 3-Deazaneplanocin A (DZNep) hydrochloride , 3-Deazaneplanocin A (DZNep) hydrochloride supplier , purchase 3-Deazaneplanocin A (DZNep) hydrochloride , 3-Deazaneplanocin A (DZNep) hydrochloride cost , 3-Deazaneplanocin A (DZNep) hydrochloride manufacturer , order 3-Deazaneplanocin A (DZNep) hydrochloride , high purity 3-Deazaneplanocin A (DZNep) hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: